Abstract
When the initial clinical trials of clofibrate had been completed and when it seemed fairly certain that this drug had no toxic effects and only minimal side effects, a formal trial was established to determine whether reduction of elevated serum cholesterol levels would be associated with a lower morbidity and mortality rate in patients with established ischemic heart disease. This was begun in 1965 and was completed in 1970.
On behalf of a Research Committee of the Scottish Society of Physicians.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Report by a Research Committee of the Scottish Society of Physicians, “Ischaemic Heart Disease: A Secondary Prevention Trial using Clofibrate.” Brit. Med. J. 4: 775 (1971).
Five year study by a group of physicians of the Newcastle upon Tyne region, “Trial of Clofibrate in the Treatment of Ischaemic Heasrt Disease.” Brit. Med. J. 4: 767 (1971).
Dewar, H. A. and M. F. Oliver. A Joint Commentary on the Newcastle and Scottish Trials. Brit. Med. J. 4: 784 (1971).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1972 Springer Science+Business Media New York
About this chapter
Cite this chapter
Oliver, M.F. (1972). Ischemic Heart Disease: A Secondary Prevention Trial Using Clofibrate (Atromid-S). In: Holmes, W.L., Paoletti, R., Kritchevsky, D. (eds) Pharmacological Control of Lipid Metabolism. Advances in Experimental Medicine and Biology, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-7547-0_21
Download citation
DOI: https://doi.org/10.1007/978-1-4684-7547-0_21
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-7549-4
Online ISBN: 978-1-4684-7547-0
eBook Packages: Springer Book Archive